COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Short Interest Update

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) was the target of a large growth in short interest in January. As of January 30th, there was short interest totaling 6,208,105 shares, a growth of 23.3% from the January 15th total of 5,033,852 shares. Based on an average daily trading volume, of 1,236,585 shares, the short-interest ratio is presently 5.0 days. Currently, 6.7% of the company’s stock are sold short. Currently, 6.7% of the company’s stock are sold short. Based on an average daily trading volume, of 1,236,585 shares, the short-interest ratio is presently 5.0 days.

COMPASS Pathways Price Performance

NASDAQ CMPS opened at $5.81 on Tuesday. The company has a market cap of $557.88 million, a price-to-earnings ratio of -2.14 and a beta of 1.92. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.23 and a quick ratio of 1.23. The stock’s fifty day moving average price is $6.74 and its 200 day moving average price is $5.87. COMPASS Pathways has a 1 year low of $2.25 and a 1 year high of $8.20.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Morgan Stanley boosted their price objective on shares of COMPASS Pathways from $10.00 to $11.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Royal Bank Of Canada upped their price target on COMPASS Pathways from $16.00 to $21.00 and gave the stock an “outperform” rating in a research report on Friday, January 23rd. Compass Point set a $15.00 price objective on COMPASS Pathways in a report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of COMPASS Pathways in a research note on Wednesday, January 21st. Finally, Lifesci Capital upgraded COMPASS Pathways to a “strong-buy” rating in a research note on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.11.

Institutional Investors Weigh In On COMPASS Pathways

A number of institutional investors and hedge funds have recently modified their holdings of CMPS. Advisory Services Network LLC purchased a new stake in COMPASS Pathways in the third quarter valued at approximately $41,000. China Universal Asset Management Co. Ltd. lifted its stake in COMPASS Pathways by 46.7% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company’s stock valued at $51,000 after acquiring an additional 5,817 shares during the period. BIT Capital GmbH purchased a new stake in shares of COMPASS Pathways in the 3rd quarter valued at $54,000. Conservest Capital Advisors Inc. boosted its holdings in shares of COMPASS Pathways by 32.5% in the 2nd quarter. Conservest Capital Advisors Inc. now owns 20,363 shares of the company’s stock valued at $57,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Northeast Financial Consultants Inc acquired a new stake in shares of COMPASS Pathways in the second quarter worth $59,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

About COMPASS Pathways

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.